News >

Potential Immunotherapy Response Markers Emerge in Metastatic Breast Cancer

Ellie Leick
Published: Tuesday, Feb 04, 2020

James M. Reuben, PhD, MBA, a professor in the Department of Hematopathology at The University of Texas MD Anderson Cancer Center

James M. Reuben, PhD, MBA

Data suggest that baseline T-cell clonality and exhaustion markers have significant translational relevance and can serve as prognostic factors of response to pembrolizumab (Keytruda) as maintenance therapy in metastatic breast cancer, explained James M. Reuben, PhD, MBA.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication